近年来,随着基因组技术和分析方法的传播,遗传性遗传疾病以及各种癌症的差异诊断,预后的确定,该疾病的后果在开创性速度方面发展了发展。基因组方法,可快速,同时确定患者基因组中的遗传或体细胞突变,为更快地检测原始治疗目标铺平了道路。基因组分析方法包括整个基因组序列(WGS),整个外部布置(WES)和靶向排列以及整个转录序列(WTS)。可能与癌症和其他遗传疾病发展有关的许多突变和转录已通过诸如整个外部排列,整个基因组序列和所有转缩序列等方法确定。在多种突变共同促进的遗传疾病中,特殊设计的靶向基因面板在诊断和预后改善的背景下具有巨大的潜力。此外,通过超靶向的序列确定循环无DNA突变的是诊断遗传疾病,包括癌症,预后和对治疗反应的估计。通过基因组分析也可以使用有关Covid-19疾病对我们当前生活的临床重要信息。在本书部分中,它重点介绍了基因组方法在生物多样性领域的当前和潜在应用。近年来基因组方法中最突出的方法之一是通过CRISPR-CAS9进行的基因组调节,此方法的各种应用为遗传疾病和基因表征提供了机会。
香烟是许多疾病的原因之一,是每年造成500万人死亡的死亡原因之一。成瘾是由吸烟引起的最重要的综合症之一,与它所含有的尼古丁有关。吸烟成瘾的原因已通过不同的成分进行了深入研究。流行病学,药理,神经生物学和遗传研究是主要研究领域。香烟和尼古丁成瘾的遗传学已经工作了50年。首先,双胞胎,家庭和收养研究表明,香烟成瘾存在遗传过渡。分子遗传研究已显示与香烟和尼古丁和候选基因的量相关。引发了许多研究是一种高度遗传性疾病,并试图使用位置遗传学来启发可疑的基因。候选基因研究还使用了香烟成瘾的遗传解剖。这两种方法对我们对过去20年中疾病的病理生理学的理解产生了重大影响。在卷烟成瘾中,研究了整个基因组的关联研究,并确定副本数量的变化也可能在不久的将来做出重大贡献。新研究表明,DNA和周围组蛋白的表观遗传机制或化学标记是终生变量,可以通过环境因素来改变。表观遗传机制一直是一种有吸引力的分子,可以解释环境条件对精神分裂症的影响。在本文中,已经回顾了从经典遗传学研究到新的表观遗传学方法中香烟成瘾中遗传研究的发展。
1 肯尼亚技术大学天文与空间科学系,内罗毕 PO Box 52428-00200,肯尼亚 2 联合国非洲区域空间科学和技术教育中心 - 英语,Ile-Ife 220882,尼日利亚;tunderabiu@arcsstee.org.ng 3 索邦大学,巴黎理工学院 萨克雷大学,等离子体物理实验室 (LPP),75005 巴黎,法国;christine.amory@lpp.polytechnique.fr 4 实验室 Lab-STICC,UMR 6285,Institut Mines-Telecom Atlantique,CEDEX 3,29288 Brest,法国;rolland.fleury@imt-atlantique.fr 5 南非国家空间局,Hermanus 7200,南非;pjcilliers@sansa.org.za (PJC); jhabarulema@sansa.org.za (J.-BH) 6 阿波美卡拉维大学物理系,科托努 01 BP 526,贝宁; adechinan.joseph@unstim.bj 7 CRASTE-LF,拉巴特 10090,摩洛哥; craste@emi.ac.ma 8 高能物理和天体物理实验室,Oukaïmeden 天文台,卡迪伊亚德大学,FSSM,马拉喀什 BP 2390,摩洛哥; a.bounhir@um5r.ac.ma 9 穆罕默德五世大学拉巴特科学院,Rabat BP 1014,摩洛哥 10 Istituto Nazionale di Geofisica e Vulcanologia,40128 Bologna,意大利; claudio.cesaroni@ingv.it 11 马里恩·恩瓜比大学大气物理实验室,布拉柴维尔 BP 69,刚果;bvs_dinga@yahoo.fr 12 波士顿学院科学研究所(ISR),马萨诸塞州栗树山 02467,美国;patricia.doherty@bc.edu 13 塞内加尔提埃斯大学理学院,提埃斯 BP 967;idrissa.gaye@univ-thies.sn 14 突尼斯埃尔马纳尔大学理学院原子、分子和应用光谱实验室(LSAMA),突尼斯邮政信箱 2092,突尼斯; hassen.ghalila@fst.utm.tn 15 材料科学和太阳能实验室(LASMES),航空学和地磁学部,阿比让 01 BPV 34 01,科特迪瓦;franck.grodji@univ-fhb.edu.ci 16 金沙萨大学工程学院,金沙萨 XI PO Box 202,刚果民主共和国;bkahindo@unikin.ac.cd 17 埃及-日本科技大学基础与应用科学研究所(E-JUST),埃及亚历山大 21500;ayman.mahrous@ejust.edu.eg 18 埃博洛瓦大学高等技术师范学院测绘系,喀麦隆 Bambili PO Box 39; honore.messanga@univ-yaounde1.cm 19 穆尼大学物理系,阿鲁阿市,邮政信箱 725,乌干达;p.mungufeni@muni.ac.ug 20 阿卜杜勒萨拉姆国际理论物理中心,34137 的里雅斯特,意大利;bnava@ictp.it 21 巴赫达尔大学 Washera 地球空间与雷达科学研究实验室,巴赫达尔,邮政信箱 79,埃塞俄比亚;melessewnigussie@yahoo.com 22 普瓦尼大学物理系,基利,邮政信箱 195-80108,肯尼亚;j.olwendo@pu.ac.ke 23 夸梅恩克鲁玛大学,卡布韦,邮政信箱 80404,赞比亚;patrick.sibanda@nkrumah.edu.com 24 国家气象研究所,科纳克里 BP 566,几内亚; rene-tato.loua@univ-reunion.fr 25 教育学院数学与科学系,卢旺达大学,卢旺达基加利 3446; j.uwamahoro@ur.ac.rw 26 地球物理实验室,FSTGAT,BP32 USTHB,Bab-Ezzouar,阿尔及尔 16123,阿尔及利亚; 27 纳齐博尼大学,布基纳法索博博迪乌拉索 01 BP 1091; * 联系方式:paulbaki@tukenya.ac.ke Doherty 对本文的早期版本做出了宝贵贡献,但于 7 月 14 日去世
隐喻对确定公司的目标受众、进行正确的市场细分和市场定位、衡量产品相关广告的有效性以及建立品牌忠诚度等许多问题都有很大的影响。隐喻,用最简单的话来说,就是用已知事物解释未知事物的艺术。 “隐喻不仅将联想从以前的经历转移到新的经历,它们还可以作为简写帮助人们理解消费者体验主张及其对他们生活的意义”(McCallion,2009)。人与产品之间也存在着沟通,因此产品也承载着一定的信息。 “隐喻已被用来创建品牌标识、营销具体产品和服务、制定营销策略、创建市场研究概念以及定义买卖双方的关系”(Çorbacıoğlu,2022 年,第 3500 页)。使用 Zaltman 隐喻引出技术 (ZMET) 对 14 名美国消费者进行的访谈结果表明,隐喻对于理解消费者对广告的印象以及他们与广告相关的含义有很大帮助 (Coulter 等人,2001 年,第 1 页)。 “这两个被相互比较的事物在正常过程中并不相关;然而,大脑可以通过发挥想象力来理解新的隐喻”(Parsa and Olgundeniz,2014,第 3 页)。我们试图通过基本的推理过程来理解隐喻的含义,并创建心理模型。 “通过隐喻渗透心灵是认知无意识定位的有效方法”(Zaltman,2003 年,第 73 页)。这样,就可以获得有关消费者隐藏或显露需求的深层有用信息。这些见解有助于广告吸引消费者的注意力并激励他们采取行动(Zaltman 和 Coulter,1995 年,第 49 页)。因此,定性的 ZMET 研究可以帮助消费者了解他们更深层次的想法和情感
Bu çalışmada Phe-Phe ve Val-Ala dipeptitlerinin kendiliğinden düzenlenme mekanizmaları üzerine biyo-nano arayüzeylerin etkileri araştırılmıştır.Çeşitli fiziksel ve kimyasal dış etkilerin uygulanması ile tüp, kese, lif, yaprak, kolye, şerit, ve tel benzeri şekillerde çeşitli dipeptit temelli supramoleküler morfolojiler rapor edilmesine rağmen, dipeptitlerin yapısal farklılıklarının hem bu küçük moleküllerin çözücü türü ve nanoparçacık gibi dış etkenlere nasıl tepki gösterdiklerinin hem de peptit sırasının kendiliğinden düzenlenmeye ve ilişkili仍然需要了解对分子结构的影响。在这种情况下,检查了同步分子在各种溶剂环境中的自发排列。Phe-Phe ve Val-Ala dipeptit moleküllerinin çözücü ortamının etkisiyle çubuk, tüp, kare prizma, deniz kestanesi benzeri gibi eşsiz ve iyi düzenlenmiş yapılar oluşturabileceği gözlenmiştir.İlginç bir şekilde, peptit kaynağı olarak Val-Ala yerine Ala-Val dipeptidi kullanıldığında ise düzenlenme sonrası dipeptitlerin nihai yapılarında bariz farklılıklar görülmüştür.Bunlara ek olarak, dipeptit moleküllerinin kendiliğinden düzenlenmesi üzerine insülin ve heparin gibi bazı biyolojik moleküllerin etkisi incelenmiştir.Son olarak, dipeptit molekülleri ve nanoparçacıklar arasındaki etkileşimi anlayabilmek amacı ile farklı büyüklük ve şekilde (küresel, çubuk, üçgen prizma ve kafes) Altın nanoparçacıkların (AuNPs) ve gümüş nanoparçacıkların (AgNPs), Phe-Phe ve Val-Ala dipeptitlerinin kendiliğinden düzenlenmesi üzerine etkileri değerlendirilmiştir.AU Nanoparchacicks in cases where the size is less than 10 nm, it has been determined that both dippeptidine has no significant effects on the processes of automatically regulated, and when the nanoparchic size is greater than 10 nm, it has been seen that the Dipeptitis morphologies are formed in the form of star -like peptide structures connected to the takbir center. 纳米肌,纳米纳克斯和纳米颗粒颗粒被确定是由偶然炎的自发调节(与全球颗粒不同),并且在形态学中观察到密集堆叠的二抗炎结构的形成。 au nanoparchacicks已被证明与Phe-Phe Organojeller结合使用,并且Au nanoparchic所包含的有机夹的去喷射过程将由激光辐射控制。AU Nanoparchacicks in cases where the size is less than 10 nm, it has been determined that both dippeptidine has no significant effects on the processes of automatically regulated, and when the nanoparchic size is greater than 10 nm, it has been seen that the Dipeptitis morphologies are formed in the form of star -like peptide structures connected to the takbir center.纳米肌,纳米纳克斯和纳米颗粒颗粒被确定是由偶然炎的自发调节(与全球颗粒不同),并且在形态学中观察到密集堆叠的二抗炎结构的形成。au nanoparchacicks已被证明与Phe-Phe Organojeller结合使用,并且Au nanoparchic所包含的有机夹的去喷射过程将由激光辐射控制。
表88。 Öğrenci Kontenjanları ve Doluluk Oranı ................................................................ 101 Tablo 89. İkametgahın Kayıtlı Olduğu İl Bazında Öğrenci Sayıları ......................................... 101 Tablo 90. 2023 MÜYÖS Bilgileri ............................................................................................. 102 Tablo 91. 2023穆耶斯的学生人数........................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... Hizmet Birimlerinin Hasta ve Tetkik Bilgileri .......................................................... 104 Tablo 93. Nöroloji Birimleri Hizmet Bilgileri .......................................................................... 104 Tablo 94. Anabilim Dalı Bazında Hasta Sayıları ...................................................................... 105 Tablo 95. 根据部门(TL)106 106表96的总交易金额。 Radyolojik Tetkik Adedi .......................................................................................... 107 Tablo 97. Mediko-Sosyal Hizmet Bilgileri ............................................................................... 108 Tablo 98. yemek hizmeti verenyerleşkeler......................................................................................................................................................................................................................................................... 2023 Yılı Yemek Ücretleri ....................................................................................... 109 Tablo 100. 2023 Yılı Yemek Hizmetinden Yararlanan Kişi Sayısı ............................................ 109 Tablo 101.表88。Öğrenci Kontenjanları ve Doluluk Oranı ................................................................ 101 Tablo 89.İkametgahın Kayıtlı Olduğu İl Bazında Öğrenci Sayıları ......................................... 101 Tablo 90.2023 MÜYÖS Bilgileri ............................................................................................. 102 Tablo 91.2023穆耶斯的学生人数........................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... .......................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................Hizmet Birimlerinin Hasta ve Tetkik Bilgileri .......................................................... 104 Tablo 93.Nöroloji Birimleri Hizmet Bilgileri .......................................................................... 104 Tablo 94.Anabilim Dalı Bazında Hasta Sayıları ...................................................................... 105 Tablo 95.根据部门(TL)106 106表96的总交易金额。Radyolojik Tetkik Adedi .......................................................................................... 107 Tablo 97.Mediko-Sosyal Hizmet Bilgileri ............................................................................... 108 Tablo 98.yemek hizmeti verenyerleşkeler.........................................................................................................................................................................................................................................................2023 Yılı Yemek Ücretleri ....................................................................................... 109 Tablo 100.2023 Yılı Yemek Hizmetinden Yararlanan Kişi Sayısı ............................................ 109 Tablo 101.Kültürel Kurslar .................................................................................................... 111 Tablo 102.faaliyetTürlerivesayıları.................................................................................................................................................................................................................................Şehir İçi ve Şehirler Arası Görev Sayıları .............................................................. 114 Tablo 104.2023 Yılı Öğrenci Ring Seferleri ............................................................................. 115 Tablo 105.Üniversite Araç Bilgileri ........................................................................................ 115 Tablo 106.İş Makinası Bilgileri ............................................................................................... 116 Tablo 107.Kiralık Araç Bilgileri ............................................................................................... 116 Tablo 108.Kulüp İsimleri........................................................................................................ 116 Tablo 109.bilimsel projesayılarıBilgileri.................................................................................................................................................................................................................................................................按菲尔德人对科学研究项目的分配和预算。122表111。Birimlere Göre Proje Sayıları ve Bütçeleri ............................................................ 124 Tablo 112.BAPKO Bütçesinden Yapılan Harcamalar ............................................................. 125 Tablo 113.Birimlere Göre TÜBİTAK Proje Bilgileri ................................................................ 126 Tablo 114.diğerProjeler ve bilgileri .................................................................................................................................................................................................................................................................................................................2023YılındaYapılanPateNtBaşvuruları.........................................................................................................................................................................................................................................................................................................................................2023年的专利注册2023年制作的有用模型应用Bilimsel Hakemliklerin Yıllara Göre Dağılımı ........................................................ 131 Tablo 119.2023 Yılında Tamamlanan Bilimsel Araştırma Projelerinden Üretilen Yayın Tablosu ................................................................................................................................... 131 Tablo 120.Akademik Teşvik Alan Öğretim Elemanı Dağılımı ................................................ 131 Tablo 121.Kurumsal İletişim Koordinatörlüğü Faaliyet Verileri ............................................ 132 Tablo 122.Marmara Üniversitesi Sosyal Medya Durum Analizi ............................................ 133 Tablo 123.Kariyer Merkezi Faaliyetleri .................................................................................. 133 Tablo 124.Bursa Alan Öğrenci Sayısı .................................................................................................................................................................................................................................................................................................................................................ERASMUS Gelen-Giden Öğrenci Sayıları .............................................................. 138 Tablo 126.伊拉斯mus人数............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. ............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. ............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. ................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... ............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. ................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... ............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. ...................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................MarmaraüniversItesiuluslararasıAnlaşmalarve te原子器.................................................................................................................................................................................................................................................................................................................................................................................................Farabi Değişim Programı İkili Anlaşmalar ............................................................ 153 Tablo 129.eğitim-ÖğretimDönemlerineGörefarabiöğrenciSayıları.......................................................................................................................................................................................................................................................Mahkeme Dava Bilgileri ....................................................................................... 156 Tablo 131.Numerical data on the cases where our university is dealing with ......................... 157 Table 132. 在2023年开放并转移了...Numerical data on the cases where our university is dealing with ......................... 157 Table 132.在2023年开放并转移了...
编辑委员会博士Mustafa Necmiİlhan博士 - 加兹大学 - Özlemçakir博士 - DokuzEylül大学协会。MehmetMerveÖzaydın-AnkaraHacıBayramVeli University Assoc。
用于测定抗逆转录病毒药物20030154的分光光度法方法20030154İpekoguz用于分析抗心律失常药物色谱方法色谱方法20030134 Ertem证人fostemsavir含量含有含有Fostemsavir 20030162 ezer pictrictical System libobirtin biobobelirtirin litrululululululululululirtirin forsemsavir量2003016666666666666666rukiyeöztürk药物分析分子抑制了基于聚合物的基于聚合物的电化学传感器20030181BüşraTekinTekin Micro -right技术在药物分析中使用的技术用途 electrochemical methods of the 20030094 Beyza Nur Çammelik Authorities Analytic Methods Analysis 20030161 Kadriye İrem Özer Spectrophotometric methods quantity determinations 20030099 Ayla Nur Dalkıran Quantity Determination by chemometric methods 20030069 Güzin Sude Aradan Supercritic Fluid Chromatography and Applications 20030147 Habibe Kurt分析化学协会。MehmetGökhançağlayanGümüş银弗洛米特钴确定纳米动物20030200ülkünisayılmaz分析化学合作伙伴。Sevinçkurbanoğlu3D医学诊断应用中的印刷电化学传感器20030353旋律PAK碳糕点电极在药物分析中使用20030090VEDATCOşkunyürek电化学传感器,用于确定Aflatoksin 20030160 Zeynep jaterynep jaterynep jaterynep jaterynep jaterynep jaterynep jaterynep jaterynep jaterynep jaterynep jaterynep jaterynep jaterynep jateryrema(vasabi; brassicaceae)植物,食品和医疗价值20030322 LeylaKhalılovacydonia cydonia oblonga mill。(ayva)植物食品和医疗价值20030184 Ahmet Kerem当前对TürkNutrasötics的看法:未来17030220 DIDEM BAHAR KARAKAYA DIOTOMIC MICRALGAS药物和生物医学应用的关键概念和期望。 Divi Divi Divi Divi)。在Artocarpus Heterophylus 20030164ÖzgeOztekinLam方面的重要性。(Moraceae)工厂的医学重要性20030137ElifTürküKayaconfolvulus L.药物植物学的重要性20030188AycaünaUnal常规药物植物学的植物的重要性,含有20030113 Ece Ece Ece ece ece ece eraslan tamarindus indaimental in Injeyneme olaea olea opimate opimateimentimentimention。 Zafer Bayram Sweatters Effects of 20030167 Feyza Özyıldırım Salıtır Characteristics and Duties 20030136 Nesibe Rana Rana Benefits and Lack of Vitamin A Family Fataman Acids 20030116 20030183 Ceren Tuğrul Mitochondria Transplantation: Basic Principles and Applications 20030126 Beyza Nur Gülhan Mitochondri Dysfunction and Cancer Relationship 20030142 Elif Ayca Elif Ayca Medical Applications of Mitochondria Transplantation: Potential Use in Disease Treatments 20030141 ELİF Su HUF GLOSEMENT EFFECTS (Applied) 20030205 Mustafa Zengin Biochemical Control of Appetal 20030101 Zehra Delialioğlu Hormones Related to Calcium Metabolism 20030195 Emine与过氧化物有关的aynuryıldız相关疾病20030045 Aytac Nur novruz生物技术处理产品和应用20030288 20030168Hilalözyürek药物nilüfernilüferyükselYükselnanoparticar nanoparticar nanoparticar Pharmaceary Carrier Systems and Prininization <2003030303030330332 SETU>
4BIO Capital 4D Molecular Tx AABB Abeona Tx Accelerated Bio ACF Bioservices Adaptimmune Adicet Bio Adverum Bio AGTC Aivita Biomedical Akouos Akron Bio Albumedix Aldevron Alpha-1 Foundation YTE Angiocrine Bio apceth Biopharma Archbow Consulting Artiva Bio Aruvant Aseptic Technologies ASGCT AskBio Aspect Biosystems Asset Management Company Association of Clinical Research Organizations Be the Match Biotherapies Beam Tx Bellicum Pharma BioBridge Global BioCardia BioLife Solutions BioMarin BioStage Biotech Mountains Blood Centers of America gene (BMS) CEO Council for Growth CGT Catapult Cell Medica Cellatoz CellCAN Cellect Bio CellGenix Cello Health CBMG Cellular Technology Limited CCRM Century Tx Cevec Chemelot CIRM City of Hope Cleveland Clinic Cleveland Cord Blood Center Gene Cook Myosite Cornell University Covance CRISPR Tx Cryoport Systems CSL CTI Clinical Trial and Consulting Services CureDuchenne Cynata Tx Dark Horse Consulting DiscGenics EB Research Partnership Editas Medicine Elevate Bio Emerging Therapy Solutions Encoded Tx Enzyvant Tx ERA Consulting Ex CellThera Exogrades Falcon Tx FARA Fate Tx Fibrocell Science Fight Colorectal Cancer Flexion Tx Foundation Telethon Foundation for Biomedical Research and Innovation GammaDelta Tx G-CON Manufacturing GE Healthcare GE2P2 Global Foundation Gemini BioProducts Generation Bio GENETHON Genprex GenSight Biologics Gift of Life Marrow Registry Gilead/Kite Giner GlaxoSmithKline Global Genes GPB Scientific Gyroscope Tx Halloran Consulting Healios KKHistogen 日立化学 Advanced Tx Solutions Hogan Lovells Homology Medicines Humanscape Huron Consulting Hybrid Concepts International ICON Immusoft InRegen InsightRX Intellia Tx Invetech Invitria Invitrx Iovance IQVIA ISCT ISSCR IVERIC Bio 约翰霍普金斯大学 强生公司 Key Biologics Kiadis Pharma Kimera Labs Kytopen L7 Informatics LabConnect Lake Street Capital Markets Latham BioPharma LatticePoint Consulting Legend Biotech Locate Bio LogicBio Lonza Biologics Lovelace Biomedical Ludwig Boltzmann Institute Lysogene Magenta Tx Mammoth Bio MaSTherCell MaxCyte MEDIPOST America Medpace MeiraGTx MSK Cancer Center Mesoblast Limited MilliporeSigma MiMedx Minerva Bio Miromatrix Medical Missouri Cures MolMed 肌肉骨骼移植基金会 Mustang Bio 国家疾病研究交流中心 美国国家多发性硬化症协会 美国国家干细胞基金会内布拉斯加州救命疗法联盟 NeoProgen 神经干细胞研究所 Neurogene 新泽西创新研究所 纽约干细胞基金会 NexImmune NIIMBL Nkarta 西北大学综合移植中心 Novadip Bio 诺华 / Avexis Novitas Capital Novo Nordisk NYBC Obsidian Odylia Tx OIRM Oisin Bio OncoSenX Opsis Tx Orchard Tx Organabio Orgenesis Orig3n Oxford BioMedica panCELLa Parent Project 肌肉萎缩症 PDC*line Pharma SA 辉瑞 Pluristem Tx PolarityTE Polyplus-transfection Poseida Tx Precigen Precision Bio Prevail Tx 预防癌症基金会项目 8p Project Farma Promethera Bio PTC Tx Recardio Recombinetics Regenerative Patch Technologies ReGenesys Regeneus REGENXBIO REMEDI ReNeuron RepliCel Life Sciences Rescue Hearing Rexgenero Rigenerand Rocket Pharma RoosterBio Roslin CT Rousselot RxGen SanBio Sanford Health Sanford 干细胞临床中心 @ UCSD Sangamo Tx Sanofi Sarepta Sartorius Stedim North America SCM LifeScience 苏格兰国家输血服务中心 Semma Tx Seneca Bio Senti Biosiences Sentien Bio Seraxis Sernova Sigilon Sirion Biotech Skyland Analytics SmartPharm Tx Solid Bio Spark Tx StafaCT Starfish Innovations STEL Technologies StemBioSys StemCyte StemExpress Stempeutics Stop ALD Foundation 干细胞研究学生协会 Sven Kili Consulting Synpromics T-Knife Tacitus Tx Takeda Talaris Tx Tenaya TERMIS-Americas Terumo BCT Tessa Tx 德克萨斯心脏研究所 迈克尔·J·福克斯基金会 Theradaptive Thermo Fisher Scientific ThermoGenesis TikoMed Tmunity Tx TrakCel TreeFrog Tx Tremont Tx LLC Trizell 杜兰大学 UCSD干细胞计划 Ultragenyx 麻省大学医学院 Unicyte uniQure Unite 2 抗击麻痹 退伍军人事务部脊髓联合协会 安第斯大学 科罗拉多大学 宾夕法尼亚大学 Unum Tx VERIGRAFT ViaCyte VidaCel Videregen Vigene VINETI ViveBiotech Vivet Tx Voisin Consulting Voyager Tx WiCell WindMIL Tx World Courier 无锡 Xintela Xyphos Bio Yposkesi Zelluna Ziopharm 肿瘤学福克斯基金会 Theradaptive 赛默飞世尔科技 ThermoGenesis TikoMed Tmunity Tx TrakCel TreeFrog Tx Tremont Tx LLC Trizell 杜兰大学 加州大学圣地亚哥分校干细胞计划 Ultragenyx 麻省大学医学院 Unicyte uniQure Unite 2 抗击麻痹 退伍军人事务部联合脊髓协会 安第斯大学 科罗拉多大学 宾夕法尼亚大学 Unum Tx VERIGRAFT ViaCyte VidaCel Videregen Vigene VINETI ViveBiotech Vivet Tx Voisin Consulting Voyager Tx WiCell WindMIL Tx 世界快递 无锡新泰拉 Xyphos Bio Yposkesi Zelluna Ziopharm 肿瘤学福克斯基金会 Theradaptive 赛默飞世尔科技 ThermoGenesis TikoMed Tmunity Tx TrakCel TreeFrog Tx Tremont Tx LLC Trizell 杜兰大学 加州大学圣地亚哥分校干细胞计划 Ultragenyx 麻省大学医学院 Unicyte uniQure Unite 2 抗击麻痹 退伍军人事务部联合脊髓协会 安第斯大学 科罗拉多大学 宾夕法尼亚大学 Unum Tx VERIGRAFT ViaCyte VidaCel Videregen Vigene VINETI ViveBiotech Vivet Tx Voisin Consulting Voyager Tx WiCell WindMIL Tx 世界快递 无锡新泰拉 Xyphos Bio Yposkesi Zelluna Ziopharm 肿瘤学福克斯基金会 Theradaptive 赛默飞世尔科技 ThermoGenesis TikoMed Tmunity Tx TrakCel TreeFrog Tx Tremont Tx LLC Trizell 杜兰大学 加州大学圣地亚哥分校干细胞计划 Ultragenyx 麻省大学医学院 Unicyte uniQure Unite 2 抗击麻痹 退伍军人事务部联合脊髓协会 安第斯大学 科罗拉多大学 宾夕法尼亚大学 Unum Tx VERIGRAFT ViaCyte VidaCel Videregen Vigene VINETI ViveBiotech Vivet Tx Voisin Consulting Voyager Tx WiCell WindMIL Tx 世界快递 无锡新泰拉 Xyphos Bio Yposkesi Zelluna Ziopharm 肿瘤学福克斯基金会 Theradaptive 赛默飞世尔科技 ThermoGenesis TikoMed Tmunity Tx TrakCel TreeFrog Tx Tremont Tx LLC Trizell 杜兰大学 加州大学圣地亚哥分校干细胞计划 Ultragenyx 麻省大学医学院 Unicyte uniQure Unite 2 抗击麻痹 退伍军人事务部联合脊髓协会 安第斯大学 科罗拉多大学 宾夕法尼亚大学 Unum Tx VERIGRAFT ViaCyte VidaCel Videregen Vigene VINETI ViveBiotech Vivet Tx Voisin Consulting Voyager Tx WiCell WindMIL Tx 世界快递 无锡新泰拉 Xyphos Bio Yposkesi Zelluna Ziopharm 肿瘤学福克斯基金会 Theradaptive 赛默飞世尔科技 ThermoGenesis TikoMed Tmunity Tx TrakCel TreeFrog Tx Tremont Tx LLC Trizell 杜兰大学 加州大学圣地亚哥分校干细胞计划 Ultragenyx 麻省大学医学院 Unicyte uniQure Unite 2 抗击麻痹 退伍军人事务部联合脊髓协会 安第斯大学 科罗拉多大学 宾夕法尼亚大学 Unum Tx VERIGRAFT ViaCyte VidaCel Videregen Vigene VINETI ViveBiotech Vivet Tx Voisin Consulting Voyager Tx WiCell WindMIL Tx 世界快递 无锡新泰拉 Xyphos Bio Yposkesi Zelluna Ziopharm 肿瘤学福克斯基金会 Theradaptive 赛默飞世尔科技 ThermoGenesis TikoMed Tmunity Tx TrakCel TreeFrog Tx Tremont Tx LLC Trizell 杜兰大学 加州大学圣地亚哥分校干细胞计划 Ultragenyx 麻省大学医学院 Unicyte uniQure Unite 2 抗击麻痹 退伍军人事务部联合脊髓协会 安第斯大学 科罗拉多大学 宾夕法尼亚大学 Unum Tx VERIGRAFT ViaCyte VidaCel Videregen Vigene VINETI ViveBiotech Vivet Tx Voisin Consulting Voyager Tx WiCell WindMIL Tx 世界快递 无锡新泰拉 Xyphos Bio Yposkesi Zelluna Ziopharm 肿瘤学福克斯基金会 Theradaptive 赛默飞世尔科技 ThermoGenesis TikoMed Tmunity Tx TrakCel TreeFrog Tx Tremont Tx LLC Trizell 杜兰大学 加州大学圣地亚哥分校干细胞计划 Ultragenyx 麻省大学医学院 Unicyte uniQure Unite 2 抗击麻痹 退伍军人事务部联合脊髓协会 安第斯大学 科罗拉多大学 宾夕法尼亚大学 Unum Tx VERIGRAFT ViaCyte VidaCel Videregen Vigene VINETI ViveBiotech Vivet Tx Voisin Consulting Voyager Tx WiCell WindMIL Tx 世界快递 无锡新泰拉 Xyphos Bio Yposkesi Zelluna Ziopharm 肿瘤学福克斯基金会 Theradaptive 赛默飞世尔科技 ThermoGenesis TikoMed Tmunity Tx TrakCel TreeFrog Tx Tremont Tx LLC Trizell 杜兰大学 加州大学圣地亚哥分校干细胞计划 Ultragenyx 麻省大学医学院 Unicyte uniQure Unite 2 抗击麻痹 退伍军人事务部联合脊髓协会 安第斯大学 科罗拉多大学 宾夕法尼亚大学 Unum Tx VERIGRAFT ViaCyte VidaCel Videregen Vigene VINETI ViveBiotech Vivet Tx Voisin Consulting Voyager Tx WiCell WindMIL Tx 世界快递 无锡新泰拉 Xyphos Bio Yposkesi Zelluna Ziopharm 肿瘤学福克斯基金会 Theradaptive 赛默飞世尔科技 ThermoGenesis TikoMed Tmunity Tx TrakCel TreeFrog Tx Tremont Tx LLC Trizell 杜兰大学 加州大学圣地亚哥分校干细胞计划 Ultragenyx 麻省大学医学院 Unicyte uniQure Unite 2 抗击麻痹 退伍军人事务部联合脊髓协会 安第斯大学 科罗拉多大学 宾夕法尼亚大学 Unum Tx VERIGRAFT ViaCyte VidaCel Videregen Vigene VINETI ViveBiotech Vivet Tx Voisin Consulting Voyager Tx WiCell WindMIL Tx 世界快递 无锡新泰拉 Xyphos Bio Yposkesi Zelluna Ziopharm 肿瘤学福克斯基金会 Theradaptive 赛默飞世尔科技 ThermoGenesis TikoMed Tmunity Tx TrakCel TreeFrog Tx Tremont Tx LLC Trizell 杜兰大学 加州大学圣地亚哥分校干细胞计划 Ultragenyx 麻省大学医学院 Unicyte uniQure Unite 2 抗击麻痹 退伍军人事务部联合脊髓协会 安第斯大学 科罗拉多大学 宾夕法尼亚大学 Unum Tx VERIGRAFT ViaCyte VidaCel Videregen Vigene VINETI ViveBiotech Vivet Tx Voisin Consulting Voyager Tx WiCell WindMIL Tx 世界快递 无锡新泰拉 Xyphos Bio Yposkesi Zelluna Ziopharm 肿瘤学福克斯基金会 Theradaptive 赛默飞世尔科技 ThermoGenesis TikoMed Tmunity Tx TrakCel TreeFrog Tx Tremont Tx LLC Trizell 杜兰大学 加州大学圣地亚哥分校干细胞计划 Ultragenyx 麻省大学医学院 Unicyte uniQure Unite 2 抗击麻痹 退伍军人事务部联合脊髓协会 安第斯大学 科罗拉多大学 宾夕法尼亚大学 Unum Tx VERIGRAFT ViaCyte VidaCel Videregen Vigene VINETI ViveBiotech Vivet Tx Voisin Consulting Voyager Tx WiCell WindMIL Tx 世界快递 无锡新泰拉 Xyphos Bio Yposkesi Zelluna Ziopharm 肿瘤学福克斯基金会 Theradaptive 赛默飞世尔科技 ThermoGenesis TikoMed Tmunity Tx TrakCel TreeFrog Tx Tremont Tx LLC Trizell 杜兰大学 加州大学圣地亚哥分校干细胞计划 Ultragenyx 麻省大学医学院 Unicyte uniQure Unite 2 抗击麻痹 退伍军人事务部联合脊髓协会 安第斯大学 科罗拉多大学 宾夕法尼亚大学 Unum Tx VERIGRAFT ViaCyte VidaCel Videregen Vigene VINETI ViveBiotech Vivet Tx Voisin Consulting Voyager Tx WiCell WindMIL Tx 世界快递 无锡新泰拉 Xyphos Bio Yposkesi Zelluna Ziopharm 肿瘤学